RxDoctor Payments Data

Julius Charlie, MD

Neurology · Mesa, AZNPI 1063479707

Payments from drug & device makers

$17,224in general payments, 2019–2025

Across 1,100 payments — averaging $15.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Livanova USA, Inc.$2K
  • UCB, Inc.$1K
  • Novartis$1K
  • Teva Pharmaceuticals USA, Inc.$1K
  • Lilly USA, LLC$760
  • plus $9K from 54 others

What the payments were for

  • Speaking & faculty fees$320%
  • Travel & lodging$6884%
  • Food & beverage$16,43195%
  • Education$730%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)142$1,719
Livanova USA, Inc.29$1,619
UCB, Inc.125$1,459
Novartis114$1,411
Teva Pharmaceuticals USA, Inc.80$1,174
Lilly USA, LLC64$760
Argenx US, Inc.28$696
Biogen26$560
Sunovion Pharmaceuticals Inc.44$534
Amgen36$531
Amneal Pharmaceuticals LLC30$527
AstraZeneca22$468
Medtronic8$392
Eisai Inc.28$388
Pfizer20$371
Impel Pharmaceuticals Inc.22$338
Neurocrine Biosciences, Inc.15$279
EMD Serono, Inc.11$269
Lundbeck LLC13$262
SK Life Science, Inc.16$260
Neurelis, Inc.11$221
Biohaven Pharmaceuticals, Inc.23$215
Mallinckrodt Enterprises LLC22$214
Supernus Pharmaceuticals, Inc.21$213
Jazz Pharmaceuticals Inc.11$201
Bausch Health US, LLC35$172
Acadia Pharmaceuticals Inc6$150
Biohaven Pharmaceutical Holding Company Ltd.16$138
Harmony Biosciences LLC7$132
Bristol Myers Squibb5$125
Axsome Therapeutics, Inc.3$100
Sanofi6$96
Otsuka America Pharmaceutical, Inc.3$90
Vanda Pharmaceuticals Inc.5$87
Merz Pharmaceuticals, LLC3$84
Genentech USA, Inc.5$83
Kyowa Kirin, Inc.5$78
Inspire Medical Systems, Inc.1$76
Almatica Pharma LLC3$69
CSL Behring2$59
Corium, LLC3$59
Mallinckrodt Hospital Products Inc.3$55
Tanabe Pharma America, Inc.3$50
Abbott2$47
Johnson & Johnson2$42
Sumitomo Pharma America, Inc.3$41
Aquestive Therapeutics, Inc.2$32
Acorda Therapeutics, Inc2$32
GE HealthCare1$29
Otto Bock Healthcare LP1$25
Arbor Pharmaceuticals, Inc.2$24
Alnylam Pharmaceuticals Inc.1$23
Boston Scientific1$22
Upsher-smith Laboratories LLC1$20
Merck1$17
Tonix Medicines, Inc.1$17
Ultragenyx Pharmaceutical Inc.1$16
Azurity Pharmaceuticals, Inc.1$15
ANI Pharmaceuticals, Inc.1$13
Avanir Pharmaceuticals, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,224 in reported general payments places this provider in the 65th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$186,183
Medicare patients
339
Services billed
2,695

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate18$151,771
BotoxOnabotulinumtoxina50$51,349
Emgality PenGalcanezumab-Gnlm69$50,775
QuliptaAtogepant28$49,588
BriviactBrivaracetam28$48,954
Nurtec OdtRimegepant Sulfate22$28,737
BelsomraSuvorexant35$22,690
RytaryCarbidopa/Levodopa11$20,375
Aimovig AutoinjectorErenumab-Aooe21$16,720
NamzaricMemantine Hcl/Donepezil Hcl26$15,848
NeuproRotigotine12$15,306
Ajovy AutoinjectorFremanezumab-Vfrm17$13,655
UbrelvyUbrogepant11$13,084
Dalfampridine ErDalfampridine16$5,213
Lacosamide42$4,142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$279$151,77118 claims
AbbVieBotox, Qulipta, Namzaric, Ubrelvy$1,719$129,869115 claims
UCB, Inc.Briviact, Neupro$1,459$64,25940 claims
PfizerNurtec Odt$371$28,73722 claims
MerckBelsomra$17$22,69035 claims
Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide$527$21,61122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 neurology providers in Arizona.

Other neurology in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →